Ajinomoto Bio-Pharma Services India Profile
Key Indicators
- Authorised Capital ₹ 95.00 Cr
as on 31-07-2024
- Paid Up Capital ₹ 85.76 Cr
as on 31-07-2024
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 185.20 Cr
as on 31-07-2024
- Revenue -36.29%
(FY 2023)
- Profit -148.71%
(FY 2023)
- Ebitda -42.92%
(FY 2023)
- Net Worth -5.42%
(FY 2023)
- Total Assets 49.33%
(FY 2023)
About Ajinomoto Bio-Pharma Services India
The Corporate was formerly known as Granules Omnichem Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 95.00 Cr and a paid-up capital of Rs 85.76 Cr.
The company has closed loans amounting to ₹185.20 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Ajinomoto Bio-Pharma Services India Private Limited India are Baipaneni Alekhya as COMPANY SECRETARY and Srivenkata Kuchi as Cfo. Mark Cassidy, Venkata Kakarlapudi, Patrick Craene, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233TG2011PTC076274
- Company No.
076274
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Sep 2011
- Date of AGM
08 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Paravada, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ajinomoto Bio-Pharma Services India?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Kakarlapudi  | Managing Director | 29-May-2020 | Current |
| Baipaneni Alekhya | Company Secretary | 29-May-2020 | Current |
| Srivenkata Kuchi | CFO | 28-Jun-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mark Cassidy  | Director | 20-Jun-2017 | Current |
Patrick Craene  | Director | 10-Jun-2021 | Current |
| Els Roeland | Director | 14-Apr-2023 | Current |
Financial Performance and Corporate Structure Insights of Ajinomoto Bio-Pharma Services India.
Ajinomoto Bio-Pharma Services India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 36.29% decrease. The company also saw a substantial fall in profitability, with a 148.71% decrease in profit. The company's net worth dipped by a decrease of 5.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ajinomoto Bio-Pharma Services India?
In 2023, Ajinomoto Bio-Pharma Services India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Oct 2016 | ₹61.00 Cr | Satisfied |
Deg - Deutsche Investitions - Und Entwicklungsgesellschaft Mbh Creation Date: 23 Apr 2013 | ₹62.10 Cr | Satisfied |
Ing Bank Nv Singapore Branch Creation Date: 23 Apr 2013 | ₹62.10 Cr | Satisfied |
How Many Employees Work at Ajinomoto Bio-Pharma Services India?
Ajinomoto Bio-Pharma Services India has a workforce of 159 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ajinomoto Bio-Pharma Services India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ajinomoto Bio-Pharma Services India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
